1. Safety and effectiveness of oral rivaroxaban versus standard anticoagulation for the treatment of symptomatic deep-vein thrombosis (XALIA): an international, prospective, non-interventional study 
Dr Walter Ageno, MD, Lorenzo G Mantovani, DSc, Prof Sylvia Haas, MD, Prof Reinhold Kreutz, MD, Danja Monje, Dipl Biol, Jonas Schneider, MD, Martin van Eickels, MD, Martin Gebel, PhD, Elizabeth Zell, MStat, Prof Alexander G G Turpie, MD 
The Lancet Haematology 
Volume 3, Issue 1, Pages e12-e21 (January 2016)
DOI: /S (15)
Copyright © 2016 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Early switchers were defined as patients for whom rivaroxaban was planned, but who initially received heparin or fondaparinux for at least 2–14 days, a vitamin K antagonist for 1–14 days, or both before switching to rivaroxaban. 116 patients in the rivaroxaban group and 128 in the standard anticoagulation group were lost to follow-up (see appendix p 8).
The Lancet Haematology 2016 3, e12-e21DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

3. Figure 2
Cumulative incidences of the primary safety and effectiveness endpoints in the safety population
(A) Major bleeding. (B) Recurrent VTE. (C) All-cause mortality. HR=hazard ratio. VTE=venous thromboembolism.
The Lancet Haematology 2016 3, e12-e21DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions

4. Figure 3
Relative safety and effectiveness of rivaroxaban and standard anticoagulation for selected patient subgroups in the propensity score-adjusted population
(A) Major bleeding. (B) Recurrent venous thromboembolism.*Some demographic parameters have data missing. †HR could not be calculated because of small number of events. HR=hazard ratio. CrCl=creatinine clearance.
The Lancet Haematology 2016 3, e12-e21DOI: ( /S (15) )
Copyright © 2016 Elsevier Ltd Terms and Conditions